Skip to main content
MRK logo

MRK · Merck & Co., Inc. · Documents

Track MRK — free
Market Cap
$329.65B
Shares
2.47B
Volume · Nov 20 15.61M Avg daily vol (3M) 9.91M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $65.01B up 1.3% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q3 Revenue $18.09B up 4.7% 10-Q filed Nov 4, 2026 Latest results Third-Quarter Sales Reach $18,085 Million, Up 5%; GAAP EPS $2.04 8-K filed Oct 29, 2026 Earnings call Q2 2026 earnings call Held Aug 4, 2026
2026
Nov 19
Investor event
FDA wants mature U.S. data in trials after Harmony CRL

Merck said the FDA wants trial data that include U.S. patients, after the Harmony CRL. Executives said the maturity of U.S. data matters more than the percentage of U.S. patients. They also described MK1084 as well tolerated.

5 source passages
So first of all, the U.S. is pretty clear that they want data that also includes U.S. patients, period. But we did get the Harmony CRL recently. It's not the percentage, it's the maturity that's important, and that really has made a difference for us Calderasiv, or MK1084, is exactly that. It's really well tolerated. Open the document at this passage
Nov 18
Current report 8-K Events of Nov 16
Glocer to retire from Merck board in May 2027; Baker named lead director

Thomas H. Glocer notified the Board he intends to retire at the 2027 Annual Meeting of Shareholders, with no disagreement with the Company. Douglas M. Baker, Jr. will become independent lead director effective Jan. 1, 2027, succeeding Mr. Glocer.

Director or officer change, or executive pay
3 source passages
Thomas H. Glocer gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2027 Annual Meeting of Shareholders. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role. Mr. Glocer’s retirement from the Board is not due to any disagreement with the Company with respect to any matter relating to the Company’s operations, policies or practices. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cidara acquisition carried $9.0 billion R&D charge

Merck recorded a $9.0 billion R&D charge after acquiring Cidara Therapeutics, Inc. for $9.2 billion in May 2026. Worldwide sales increased 5% to $18.1 billion in the third quarter of 2026 amid pricing pressure.

Revenue $18.09B ▲ 4.7% Net income $5.07B ▼ 12.4% Diluted EPS $2.04 ▼ 12.1%
Read from the MD&A section
3 source passages
In May 2026, Merck acquired Cidara Therapeutics, Inc. (Cidara), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $9.2 billion (including $570 million of payments to settle share-based equity awards of which $406 million related to unvested equity awards). Merck recorded a charge of $9.0 billion to Research and development expenses (which primarily represented acquired IPR&D with no alternative future use), or $3.62 per share, in the first nine months of 2026, as well as net assets of $332 million. Worldwide sales were $18.1 billion and $51.0 billion in the third quarter and first nine months of 2026, respectively, representing increases of 5% compared with the same periods of 2025, primarily driven by growth in the oncology and cardiometabolic, respiratory and specialty franchises, as well as animal health, partially offset by a decline in the vaccines and infectious diseases franchise. Open the document at this passage
Oct 29
Current report 8-K
Third-Quarter Sales Reach $18,085 Million, Up 5%; GAAP EPS $2.04

Merck reported third-quarter 2026 sales of $18,085 million, up 5%, with GAAP EPS of $2.04 and non-GAAP EPS of $2.49, both including a one-time $0.12 per share charge tied to a SciBrunch license agreement. Full-year 2026 sales are now expected between $66.8 billion and $67.3 billion. Non-GAAP EPS guidance was narrowed and raised to between $2.77 and $2.82.

Financial results Read from the first part of this long document
6 source passages
Total Sales | 18,085 | 17,276 | | 5% GAAP EPS was $2.04 for the third quarter of 2026 Non-GAAP EPS was $2.49 for the third quarter of 2026 Both GAAP and non-GAAP EPS in the third quarter of 2026 include a one-time charge of $0.12 per share related to a global license agreement with SciBrunch Therapeutics Co., Ltd. (SciBrunch). Now Expects Sales To Be Between $66.8 Billion and $67.3 Billion Narrows and Raises Expected Non-GAAP EPS Range To Be Between $2.77 and $2.82 Open the document at this passage
Oct 13
Current report 8-K Events of Oct 9
Director or officer change, or executive pay

Merck & Co., Inc. elected Paul J. Diaz to its Board of Directors effective November 1, 2026, appointed him to the Audit Committee and Research Committee, and expanded the Board to 14 members. Diaz will stand for shareholder election in May 2027.

Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $16.61B ▲ 5.1% Net loss $1.34B Diluted EPS -$0.54
May 22
Current report 8-K
Other events AI summary on its way
May 5
Tender offer SC TO-T/A
Tender offer AI summary on its way
May 4
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $16.29B ▲ 4.9% Net loss $4.24B Diluted EPS -$1.72
Apr 24
Tender offer SC TO-T/A
Tender offer AI summary on its way
Apr 8
Proxy statement DEF 14A Meeting May 26, 2026
Proxy statement AI summary on its way
Apr 7
Tender offer SC TO-T
Tender offer AI summary on its way
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $65.01B ▲ 1.3% Net income $18.25B ▲ 6.6% Diluted EPS $7.28 ▲ 8.0%
Jan 7
Tender offer SC TO-T/A
Tender offer AI summary on its way
2025
Nov 5
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $17.28B ▲ 3.7% Net income $5.79B ▲ 83.2% Diluted EPS $2.32 ▲ 87.1%
Aug 5
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $15.81B ▼ 1.9% Net income $4.43B ▼ 18.8% Diluted EPS $1.76 ▼ 17.8%
May 2
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $15.53B ▼ 1.6% Net income $5.08B ▲ 6.7% Diluted EPS $2.01 ▲ 7.5%
Feb 25
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $64.17B ▲ 6.7% Net income $17.12B ▲ 4589.6% Diluted EPS $6.74 ▲ 4714.3%
Showing 1–50 of 155 documents
Key facts CIK 310158 CUSIP 58933Y105 13F (30d) 3127 filings 2943 filers Visit website Investor relations